-
3
-
-
80053304479
-
-
Wilmington, DE: AstraZeneca Pharmaceuticals LP
-
Faslodex (fulvestrant) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.
-
(2005)
Faslodex (Fulvestrant) [Package Insert]
-
-
-
11
-
-
74549146408
-
-
Princeton, NJ: Bristol-Myers Squibb Company
-
Ixempra (ixabepilone) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2009.
-
(2009)
Ixempra (Ixabepilone) [Package Insert]
-
-
-
12
-
-
0011475181
-
-
Princeton, NJ : Bristol-Myers Squibb Company
-
Taxol (paclitaxel) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2007.
-
(2007)
Taxol (Paclitaxel) [Package Insert]
-
-
-
15
-
-
80052503758
-
-
Research Triangle Park, NC: GlaxoSmithKline
-
Tykerb (lapatinib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2008.
-
(2008)
Tykerb (Lapatinib) [Package Insert]
-
-
-
17
-
-
43949096582
-
Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice
-
DOI 10.1038/clpt.2008.55, PII CLPT200855
-
Robertson GR, Liddle C. and Clarke SJ Inflammation; altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008 ; 83: 894-897. (Pubitemid 351704929)
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.83
, Issue.6
, pp. 894-897
-
-
Robertson, G.R.1
Liddle, C.2
Clarke, S.J.3
-
18
-
-
33745574979
-
Drug interactions in cancer therapy
-
DOI 10.1038/nrc1887, PII N1887
-
Scripture CD and Figg WD Drug interactions in cancer therapy. Nat Rev Cancer 2006 ; 6: 546-558. (Pubitemid 43980543)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.7
, pp. 546-558
-
-
Scripture, C.D.1
Figg, W.D.2
-
19
-
-
0002367230
-
Principles of Therapeutics
-
Hardman J, Limbird LE and Molinoff PB (eds) 9th edn. New York, NY: The McGraw-Hill Companies
-
Nies A. and Spielberg SP Principles of therapeutics. In: Hardman J, Limbird LE and Molinoff PB (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9 th edn. New York, NY: The McGraw-Hill Companies, 1996, p. 43-45.
-
(1996)
Goodman and Gilman's the Pharmacological Basis of Therapeutics
, pp. 43-45
-
-
Nies, A.1
Spielberg, S.P.2
-
20
-
-
0032954113
-
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
-
DOI 10.1023/A:1008360406322
-
Holmes FA, Valero V., Walters RS, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results. Ann Oncol 1999 ; 10: 403-411. (Pubitemid 29236417)
-
(1999)
Annals of Oncology
, vol.10
, Issue.4
, pp. 403-411
-
-
Holmes, F.A.1
Valero, V.2
Walters, R.S.3
Theriault, R.L.4
Booser, D.J.5
Gibbs, H.6
Fraschini, G.7
Buzdar, A.U.8
Willey, J.9
Frye, D.10
Asmar, L.11
Hortobagyi, G.N.12
-
21
-
-
0034851464
-
Clinical-pharmacological strategies to assess drug interaction potential during drug development
-
Kuhlmann J. and Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001 ; 24: 715-725. (Pubitemid 32848351)
-
(2001)
Drug Safety
, vol.24
, Issue.10
, pp. 715-725
-
-
Kuhlmann, J.1
Muck, W.2
-
22
-
-
33745524017
-
Drug Interactions in Cancer Therapy: Pharmacodynamic Drug Interactions
-
Figg WD and McLeod HL (eds) Totowa, NJ: Humana Press
-
Ando Y. Drug interactions in cancer therapy: Pharmacodynamic drug interactions. In: Figg WD and McLeod HL (eds) Handbook of anticancer pharmacokinetics and pharmacodynamics. Totowa, NJ: Humana Press, 2004, p. 215-230.
-
(2004)
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
, pp. 215-230
-
-
Ando, Y.1
-
23
-
-
10944253706
-
Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy
-
DOI 10.2165/00003088-200443150-00005
-
Singh BN and Malhotra BK Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004 ; 43: 1127-1156. (Pubitemid 40013180)
-
(2004)
Clinical Pharmacokinetics
, vol.43
, Issue.15
, pp. 1127-1156
-
-
Singh, B.N.1
Malhotra, B.K.2
-
24
-
-
2942729844
-
Herbal remedies in the United States: Potential adverse interactions with anticancer agents
-
DOI 10.1200/JCO.2004.08.182
-
Sparreboom A., Cox MC, Acharya MR and Figg WD Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004 ; 22: 2489-2503. (Pubitemid 41115408)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2489-2503
-
-
Sparreboom, A.1
Cox, M.C.2
Acharya, M.R.3
Figg, W.D.4
-
29
-
-
37449028688
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
-
Forbes JF, Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008 ; 9: 45-53.
-
(2008)
Lancet Oncol
, vol.9
, pp. 45-53
-
-
Forbes, J.F.1
Cuzick, J.2
Buzdar, A.3
-
30
-
-
0034520267
-
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
-
DOI 10.1067/mcp.2000.112240
-
Durr D., Stieger B., Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 ; 68: 598-604. (Pubitemid 32059985)
-
(2000)
Clinical Pharmacology and Therapeutics
, vol.68
, Issue.6
, pp. 598-604
-
-
Durr, D.1
Stieger, B.2
Kullak-Ublick, G.A.3
Rentsch, K.M.4
Steinert, H.C.5
Meier, P.J.6
Fattinger, K.7
-
31
-
-
18244376403
-
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters
-
DOI 10.1007/s00018-002-8424-8
-
Di Pietro A., Conseil G., Perez-Victoria JM, et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 2002 ; 59: 307-322. (Pubitemid 34169516)
-
(2002)
Cellular and Molecular Life Sciences
, vol.59
, Issue.2
, pp. 307-322
-
-
Di Pietro, A.1
Conseil, G.2
Perez-Victoria, J.M.3
Dayan, G.4
Baubichon-Cortay, H.5
Trompier, D.6
Steinfels, E.7
Jault, J.-M.8
De Wet, H.9
Maitrejean, M.10
Comte, G.11
Boumendjel, A.12
Mariotte, A.-M.13
Dumontet, C.14
McIntosh, D.B.15
Goffeau, A.16
Castanys, S.17
Gamarro, F.18
Barron, D.19
-
32
-
-
69949106198
-
Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy
-
Bansal T., Jaggi M., Khar RK and Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009 ; 12: 46-78.
-
(2009)
J Pharm Pharm Sci
, vol.12
, pp. 46-78
-
-
Bansal, T.1
Jaggi, M.2
Khar, R.K.3
Talegaonkar, S.4
-
33
-
-
0031947562
-
Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice
-
DOI 10.1021/tx970192k
-
He K., Iyer KR, Hayes RN, Sinz MW, Woolf TF and Hollenberg PF Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998 ; 11: 252-259. (Pubitemid 28194348)
-
(1998)
Chemical Research in Toxicology
, vol.11
, Issue.4
, pp. 252-259
-
-
He, K.1
Iyer, K.R.2
Hayes, R.N.3
Sinz, M.W.4
Woolf, T.F.5
Hollenberg, P.F.6
-
34
-
-
15744405556
-
The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5
-
DOI 10.1124/jpet.104.079608
-
Lin HL, Kent UM and Hollenberg PF The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 2005 ; 313: 154-164. (Pubitemid 40411339)
-
(2005)
Journal of Pharmacology and Experimental Therapeutics
, vol.313
, Issue.1
, pp. 154-164
-
-
Lin, H.-L.1
Kent, U.M.2
Hollenberg, P.F.3
-
35
-
-
0034954793
-
Inhibition of P-glycoprotein transport function by grapefruit juice psoralen
-
DOI 10.1023/A:1011089924099
-
Wang EJ, Casciano CN, Clement RP and Johnson WW Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001 ; 18: 432-438. (Pubitemid 32592573)
-
(2001)
Pharmaceutical Research
, vol.18
, Issue.4
, pp. 432-438
-
-
Wang, E.-J.1
Casciano, C.N.2
Clement, R.P.3
Johnson, W.W.4
-
36
-
-
11844301652
-
Effects of dietary chemopreventive phytochemicals on P-glycoprotein function
-
DOI 10.1016/j.bbrc.2004.12.081, PII S0006291X04028736
-
Nabekura T., Kamiyama S. and Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005 ; 327: 866-870. (Pubitemid 40092828)
-
(2005)
Biochemical and Biophysical Research Communications
, vol.327
, Issue.3
, pp. 866-870
-
-
Nabekura, T.1
Kamiyama, S.2
Kitagawa, S.3
-
37
-
-
28244477789
-
Effects of St. John's wort and hypericin on cytotoxicity of anticancer drugs
-
Wada A., Sakaeda T., Takara K., et al. Effects of St. John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet 2002 ; 17: 467-474.
-
(2002)
Drug Metab Pharmacokinet
, vol.17
, pp. 467-474
-
-
Wada, A.1
Sakaeda, T.2
Takara, K.3
-
38
-
-
66949155833
-
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
-
Golden EB, Lam PY, Kardosh A., et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009 ; 113: 5927-5937.
-
(2009)
Blood
, vol.113
, pp. 5927-5937
-
-
Golden, E.B.1
Lam, P.Y.2
Kardosh, A.3
-
40
-
-
45249121177
-
Drugs behave as substrates, inhibitors and inducers of human cytochrome
-
Zhou SF Drugs behave as substrates, inhibitors and inducers of human cytochrome. P450 3A4 Curr Drug Metab 2008 ; 9: 310-322.
-
(2008)
P450 3A4 Curr Drug Metab
, vol.9
, pp. 310-322
-
-
Zhou, S.F.1
-
41
-
-
44449112267
-
Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4
-
Zhou SF Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr Pharm Des 2008 ; 14: 990-1000.
-
(2008)
Curr Pharm des
, vol.14
, pp. 990-1000
-
-
Zhou, S.F.1
-
42
-
-
70349328422
-
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
-
Ahern TP, Pedersen L., Cronin-Fenton D., et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009 ; 18: 2562.
-
(2009)
Cancer Epidemiol Biomarkers Prev
, vol.18
, pp. 2562
-
-
Ahern, T.P.1
Pedersen, L.2
Cronin-Fenton, D.3
-
43
-
-
34248208754
-
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
-
Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007 ; 9: R7.
-
(2007)
Breast Cancer Res
, vol.9
, pp. 7
-
-
Wegman, P.1
Elingarami, S.2
Carstensen, J.3
-
44
-
-
62749188875
-
Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs
-
Aszalos A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 2008 ; 9: 1010-1018.
-
(2008)
Curr Drug Metab
, vol.9
, pp. 1010-1018
-
-
Aszalos, A.1
-
45
-
-
58149127453
-
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
-
Suzuki K., Doki K., Homma M., et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2008 ; 67: 44-49.
-
(2008)
Br J Clin Pharmacol
, vol.67
, pp. 44-49
-
-
Suzuki, K.1
Doki, K.2
Homma, M.3
-
46
-
-
0036218554
-
Changes in plasma protein binding have little clinical relevance
-
DOI 10.1067/mcp.2002.121829
-
Benet LZ and Hoener BA Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002 ; 71: 115-121. (Pubitemid 34271114)
-
(2002)
Clinical Pharmacology and Therapeutics
, vol.71
, Issue.3
, pp. 115-121
-
-
Benet, L.Z.1
Hoener, B.-A.2
-
47
-
-
0035033019
-
Pharmacogenomics: Unlocking the human genome for better drug therapy
-
DOI 10.1146/annurev.pharmtox.41.1.101
-
McLeod HL and Evans WE Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001 ; 41: 101-121. (Pubitemid 32385884)
-
(2001)
Annual Review of Pharmacology and Toxicology
, vol.41
, pp. 101-121
-
-
McLeod, H.L.1
Evans, W.E.2
-
49
-
-
65649099099
-
Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: A cluster-randomized trial
-
Schnipper JL, Hamann C., Ndumele CD, et al. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: A cluster-randomized trial. Arch Intern Med 2009 ; 169: 771-780.
-
(2009)
Arch Intern Med
, vol.169
, pp. 771-780
-
-
Schnipper, J.L.1
Hamann, C.2
Ndumele, C.D.3
|